SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as investors debate whether the current price action signals a sustainable breakout or another temporary pump, with community sentiment sharply divided between long-term believers and vocal skeptics. Discussions are centered on the token's relationship with broader market movements and speculative hopes for future regulatory clarity and institutional adoption.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing a massive surge in trading volume and investor interest as the community positions itself ahead of a critical May FDA decision for its ADHD drug, CTx-1301. Investors are actively discussing the potential impact of an anticipated U.S. patent approval on the stock, drawing parallels to previous market rallies while debating the impact of recent financing moves on the company's long-term valuation.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is seeing heightened community engagement as traders react to the stock's high-beta correlation with Bitcoin and its ongoing transition into a crypto-focused treasury company. Discussion is currently polarized, with bulls pointing to the company's Bitcoin holdings and potential for long-term re-rating against net asset value, while bears frequently cite concerns over dilution, reverse splits, and the high costs of operational debt.

GODS token is the currency used in the blockchain-based online trading card game, Gods Unchained. The token will act as a governance so players will be able to decide the development direction of the game. Players can also use the token to mint rare cards. Most importantly, the GODS token will be an integral part of the play to earn concept of the game.

Gods Unchained

Gods Unchained is trending as the community speculates on a potential price breakout, citing its gaming utility and low market capitalization relative to peers as catalysts. Traders are actively debating technical patterns like the cup-and-handle and monitoring for a broader rotation into the gaming sector, with many expressing optimism for long-term growth and high-percentage gains.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) remains a major focal point as investors debate whether mining stocks can decouple from volatile gold and silver spot prices amidst ongoing geopolitical tensions and fiscal policy shifts. The community is actively discussing Elliott Wave technical patterns, potential margin calls, and the broader macro implications of central bank activity on the metals complex.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is seeing significant volatility and high trading volume following the release of promising Phase 1 expansion data for its colorectal cancer treatment, Varsetatug Masetecan. While bulls are energized by positive clinical signals and analyst price target upgrades, the community is actively debating the impact of the newly announced public offering and the long-term dilution risks inherent in clinical-stage drug development.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors debate whether potential integration into Xs upcoming payment system serves as a long-term catalyst or just a temporary pump. While some community members remain skeptical, citing historical price patterns and bearish sentiment, others are actively loading up on shares in anticipation of a significant breakout.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending amid a surge in institutional activity, highlighted by a notable streak of daily inflows into newly launched spot ETFs that continues to attract retail attention. Despite ongoing volatility and community debates over its long-term utility versus market speculation, holders remain focused on the potential impact of global regulatory milestones and increased banking partnerships on future liquidity.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to intensifying speculation surrounding its proprietary III-V-on-silicon photonics technology, which investors view as a critical, scalable solution for the power-efficiency bottlenecks in AI data centers. The community is actively discussing the stock's potential for high-volume commercial adoption, citing recent patent filings, government contracts, and the strategic addition of veteran industry leadership as key indicators that the company is transitioning from R&D to market-ready commercialization.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is seeing intense trading activity as market participants clash over conflicting narratives surrounding Middle East geopolitical disruptions and U.S. natural gas fundamentals. Community members are actively debating whether the ongoing supply-chain volatility in the Strait of Hormuz will trigger a sustained price breakout or if high storage levels and shoulder-season demand will ultimately lead to another technical collapse.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTAâ?¢, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTAâ?¢. KIACTAâ?¢ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamabâ?¢, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamabâ?¢ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Healthâ??s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

BLU
Bellus Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BLU News

BLUBellus Health Inc